小儿急性髓细胞白血病诱导后的支持治疗:患者是否应该住院?

Leukemia Research and Treatment Pub Date : 2014-01-01 Epub Date: 2014-09-29 DOI:10.1155/2014/592379
Susumu Inoue, Isra'a Khan, Rao Mushtaq, Dawn Carson, Elna Saah, Nkechi Onwuzurike
{"title":"小儿急性髓细胞白血病诱导后的支持治疗:患者是否应该住院?","authors":"Susumu Inoue,&nbsp;Isra'a Khan,&nbsp;Rao Mushtaq,&nbsp;Dawn Carson,&nbsp;Elna Saah,&nbsp;Nkechi Onwuzurike","doi":"10.1155/2014/592379","DOIUrl":null,"url":null,"abstract":"<p><p>Children with AML become profoundly neutropenic while they undergo remission induction chemotherapy. It is unknown whether these children should be kept in the hospital while they are severely neutropenic to prevent life-threatening complications associated with neutropenia and reduce fatality. We at our institution routinely discharge patients after completing remission induction chemotherapy in the presence of profound neutropenia, unless it is clinically contraindicated. We reviewed all AML patients who were consecutively treated at our hospital from 1989 to 2011. Thirteen patients were electively discharged after completion of induction I chemotherapy. Of the 13, 4 died due to relapse or complications of stem cell transplants (not due to neutropenia related complications). Another eight are long term survivors. In this very small series, discharge from the hospital even though patients were severely neutropenic did not adversely affect the survival. </p>","PeriodicalId":18102,"journal":{"name":"Leukemia Research and Treatment","volume":"2014 ","pages":"592379"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/592379","citationCount":"7","resultStr":"{\"title\":\"Postinduction Supportive Care of Pediatric Acute Myelocytic Leukemia: Should Patients be Kept in the Hospital?\",\"authors\":\"Susumu Inoue,&nbsp;Isra'a Khan,&nbsp;Rao Mushtaq,&nbsp;Dawn Carson,&nbsp;Elna Saah,&nbsp;Nkechi Onwuzurike\",\"doi\":\"10.1155/2014/592379\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Children with AML become profoundly neutropenic while they undergo remission induction chemotherapy. It is unknown whether these children should be kept in the hospital while they are severely neutropenic to prevent life-threatening complications associated with neutropenia and reduce fatality. We at our institution routinely discharge patients after completing remission induction chemotherapy in the presence of profound neutropenia, unless it is clinically contraindicated. We reviewed all AML patients who were consecutively treated at our hospital from 1989 to 2011. Thirteen patients were electively discharged after completion of induction I chemotherapy. Of the 13, 4 died due to relapse or complications of stem cell transplants (not due to neutropenia related complications). Another eight are long term survivors. In this very small series, discharge from the hospital even though patients were severely neutropenic did not adversely affect the survival. </p>\",\"PeriodicalId\":18102,\"journal\":{\"name\":\"Leukemia Research and Treatment\",\"volume\":\"2014 \",\"pages\":\"592379\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2014/592379\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia Research and Treatment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2014/592379\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2014/9/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2014/592379","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/9/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

摘要

急性髓系白血病患儿在接受缓解性诱导化疗时变得严重中性粒细胞减少。目前尚不清楚这些儿童是否应该在严重中性粒细胞减少时继续住院,以防止与中性粒细胞减少相关的危及生命的并发症并减少死亡率。在我们的机构,除非有临床禁忌症,否则患者在完成缓解诱导化疗后通常会出院。我们回顾了1989年至2011年在我院连续治疗的所有AML患者。13例患者完成诱导I期化疗后选择性出院。在13例患者中,4例死于干细胞移植的复发或并发症(非中性粒细胞减少相关并发症)。另外8人是长期幸存者。在这个非常小的系列中,即使患者严重中性粒细胞减少,出院也不会对生存产生不利影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Postinduction Supportive Care of Pediatric Acute Myelocytic Leukemia: Should Patients be Kept in the Hospital?

Children with AML become profoundly neutropenic while they undergo remission induction chemotherapy. It is unknown whether these children should be kept in the hospital while they are severely neutropenic to prevent life-threatening complications associated with neutropenia and reduce fatality. We at our institution routinely discharge patients after completing remission induction chemotherapy in the presence of profound neutropenia, unless it is clinically contraindicated. We reviewed all AML patients who were consecutively treated at our hospital from 1989 to 2011. Thirteen patients were electively discharged after completion of induction I chemotherapy. Of the 13, 4 died due to relapse or complications of stem cell transplants (not due to neutropenia related complications). Another eight are long term survivors. In this very small series, discharge from the hospital even though patients were severely neutropenic did not adversely affect the survival.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. Human T-Cell Lymphotropic Virus Types 1 and 2 Seropositivity among Blood Donors at Mbarara Regional Blood Bank, South Western Uganda Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia Isochromosome 17q in Chronic Lymphocytic Leukemia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1